Pyrosequencing Unit and Mayo Clinic to Co-Develop Test for Rare Cancer | GenomeWeb

NEW YORK, Dec. 17 — Pyrosequencing's Molecular Diagnostics Business Unit and the Mayo Clinic plan to co-develop tests for an inherited form of thyroid cancer, the two groups announced on Monday.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.